v*n
2 楼
rev is actually beat
guidance is raised 1B
guidance is raised 1B
B*n
3 楼
saw that, too
19,900 shares
19,900 shares
C*T
4 楼
明天会不会不跌反涨?这么多人买
s*1
6 楼
Product sales totaled $5.97 billion, with sales of its blockbuster antiviral
drug Sovaldi, which was launched in December 2013, slipping to $2.8 billion
from $3.48 billion in the sequential second quarter. The company also
revised its 2014 outlook for net product sales to a range of $22 billion to
$23 billion from $21 billion to $23 billion.
drug Sovaldi, which was launched in December 2013, slipping to $2.8 billion
from $3.48 billion in the sequential second quarter. The company also
revised its 2014 outlook for net product sales to a range of $22 billion to
$23 billion from $21 billion to $23 billion.
l*i
7 楼
都MISS了吧
antiviral
billion
to
【在 s****1 的大作中提到】
: Product sales totaled $5.97 billion, with sales of its blockbuster antiviral
: drug Sovaldi, which was launched in December 2013, slipping to $2.8 billion
: from $3.48 billion in the sequential second quarter. The company also
: revised its 2014 outlook for net product sales to a range of $22 billion to
: $23 billion from $21 billion to $23 billion.
antiviral
billion
to
【在 s****1 的大作中提到】
: Product sales totaled $5.97 billion, with sales of its blockbuster antiviral
: drug Sovaldi, which was launched in December 2013, slipping to $2.8 billion
: from $3.48 billion in the sequential second quarter. The company also
: revised its 2014 outlook for net product sales to a range of $22 billion to
: $23 billion from $21 billion to $23 billion.
相关阅读